Just a moment, the page is loading...

GSK-49653/096




A 26-week Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on…
rosiglitazone
49653/096
Diabetes Mellitus, Type 2
Phase 3
Extension study 49653/112 was conducted. A reporting and analysis plan is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.
July 2015